AVITA Medical’s Loan Covenant Breaches Raise Going Concern Questions

Revenue Growth and Product Expansion

AVITA Medical, a therapeutic acute wound care company, posted a 21% increase in total revenues to $18.4 million for the quarter ended June 30, 2025, compared to $15.2 million in the same period last year. This growth was primarily driven by deeper penetration of its RECELL product portfolio in existing accounts, new customer acquisitions in traumatic and surgical wound care, and the commercial launch of Cohealyx, a collagen-based dermal matrix introduced in April 2025.

The company’s flagship RECELL System, including the next-generation RECELL GO and RECELL GO mini devices, continues to gain traction in burn and trauma centers. These products leverage autologous skin cell technology to accelerate wound healing, a critical need in acute care settings.

Profitability and Cost Dynamics

Despite revenue gains, AVITA Medical reported a net loss of $9.9 million for Q2 2025, an improvement from the $15.4 million loss in the prior year quarter. Gross profit rose to $14.9 million, but the gross margin declined to 81.2% from 86.1%, reflecting the impact of volume discounts, a higher inventory reserve, and a shift in product mix. Notably, the company shares revenue on Cohealyx and PermeaDerm sales, which, while beneficial for market expansion, compresses overall margins.

Operating expenses decreased by 9% year-over-year to $26.1 million, with reductions in sales and marketing as well as general and administrative costs, partially offset by increased research and development spending. Cost savings initiatives, including a reduced sales force, contributed to lower personnel expenses.

Liquidity Challenges and Debt Covenant Waivers

AVITA Medical continues to face liquidity pressures, with cash and marketable securities totaling $15.7 million as of June 30, 2025. The company has incurred operating losses and negative cash flows since inception, culminating in an accumulated deficit of $383.6 million.

The company’s $90 million senior secured credit facility with OrbiMed Advisors includes covenants tied to trailing 12-month net revenue and minimum cash balances. AVITA Medical breached its revenue covenants for the first two quarters of 2025 but secured waivers from the lender. In August 2025, the company amended the credit agreement to ease revenue covenant thresholds through mid-2026, issuing 400,000 shares to the lender as part of the amendment consideration.

Management acknowledges substantial doubt about the company’s ability to continue as a going concern without additional funding. The company is actively exploring equity and debt financing options to bolster liquidity and sustain operations.

Strategic Outlook and Market Environment

AVITA Medical’s strategic priorities include expanding RECELL adoption in U.S. burn and trauma centers, growing market share for Cohealyx and PermeaDerm, and obtaining regulatory approvals such as the CE mark for RECELL GO to enter European and other international markets.

However, the company faces headwinds from reimbursement uncertainties, macroeconomic volatility, and geopolitical risks that could affect healthcare spending and product demand. The company has paused further investment in its vitiligo initiative due to reimbursement challenges.

Overall, AVITA Medical’s Q2 results reflect a company in transition; growing revenues and product reach while navigating financial constraints and operational risks.